Skip to main content

Paul Steven M's Form 4 filing

Alnylam Pharmaceuticals, Inc. (ALNY) · filed Apr 5, 2022

Accession no.
0001735276-22-000039
Filed
Apr 5, 2022
Trade date
Apr 1, 2022
Filing delay
4 days
Rule 10b5-1 plan
Not on the form (before 2023)

This filing lists 11 non-derivative transactions and 1 derivative transaction. Open-market sales total $2.56M. It was filed 4 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Paul Steven MCIK 0001237564Director

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Apr 1, 2022Common StockMOption exerciseAcquired+15,000$11.33+$169,95016,000Direct
Apr 1, 2022Common StockSSaleDisposed−253$166.04F2−$42,008.1215,747Direct
Apr 1, 2022Common StockSSaleDisposed−4,948$168.95F3−$835,964.610,799Direct
Apr 1, 2022Common StockSSaleDisposed−4,872$169.71F4−$826,827.125,927Direct
Apr 1, 2022Common StockSSaleDisposed−1,235$171.16F5−$211,382.64,692Direct
Apr 1, 2022Common StockSSaleDisposed−1,434$172.10F6−$246,791.43,258Direct
Apr 1, 2022Common StockSSaleDisposed−642$173.06F7−$111,104.522,616Direct
Apr 1, 2022Common StockSSaleDisposed−90$174.33−$15,689.72,526Direct
Apr 1, 2022Common StockSSaleDisposed−526$176.51F8−$92,844.262,000Direct
Apr 1, 2022Common StockSSaleDisposed−825$177.58F9−$146,503.51,175Direct
Apr 1, 2022Common StockSSaleDisposed−175$178.60−$31,2551,000Direct

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Apr 1, 2022Common StockMOption exerciseDisposed−15,000$0.00$00Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F2

Sale prices ranged from $165.91 to $166.41.

Referenced by the price of 1 transaction in Table I.

F3

Sale prices ranged from $168.30 to $169.30.

Referenced by the price of 1 transaction in Table I.

F4

Sale prices ranged from $169.32 to $170.28.

Referenced by the price of 1 transaction in Table I.

F5

Sale prices ranged from $170.70 to $171.63.

Referenced by the price of 1 transaction in Table I.

F6

Sale prices ranged from $171.75 to $172.73.

Referenced by the price of 1 transaction in Table I.

F7

Sale prices ranged from $172.83 to $173.37.

Referenced by the price of 1 transaction in Table I.

F8

Sale prices ranged from $176.04 to $176.88.

Referenced by the price of 1 transaction in Table I.

F9

Sale prices ranged from $177.12 to $178.00.

Referenced by the price of 1 transaction in Table I.

Read the full filing on SEC EDGAR (opens in a new tab)